Inhibrx reports Phase 2 HNSCC data showing INBRX-106 combo nearly doubles response rate
The company's OX40 agonist plus pembrolizumab hit 48.3% response rate versus 26.5% for pembrolizumab alone, with benefit strongest in HPV+ patients.
SEC filing
Latest
3 stories
Tuesday, September 8
Thursday, August 13
Inhibrx reports Q2 2026 results, sets Q3 PFS readout for INBRX-106
The company also drew $100 million more from Oxford Finance and got FDA filing acceptance for its ozekibart BLA in chondrosarcoma with an April 2027 goal date.
SEC filing
Thursday, July 16
Inhibrx Biosciences announces $500 million Oxford Finance credit facility, publicly discloses terms
A press release confirms the July 15, 2026 amendment details, including CFO comments tying the funding to two clinical programs awaiting data.
SEC filing